The mistakes Daiichi Sankyo made in the Ranbaxy deal

'Love for the deal' was evident when Daiichi termed the investigations by the US Foods and Drugs Administration (FDA) as just a "risk call" and did not spend enough time on evaluating the risk,......

Markets finish higher for 5th straight session; oil, metals shine

Smart rally in the oil and gas stocks and metal shares tracking a rebound in the overnight global commodity prices lifted sentiments. Markets closed higher for the fifth straight session on......

Sun Pharma open to large acquisitions post Ranbaxy

India's largest drugmaker Sun Pharmaceutical Industries Ltd will look at making more large acquisitions even as it winds up a $3.2 billion deal to buy smaller rival Ranbaxy Laboratories Ltd. The......

Sensex ends in the red amid volatile trade; IT, auto, realty fall

The 30-share Sensex ended down 30.30 points at 28,161.72 and the 50-share Nifty dipped 7.95 points at 8,542.95.  Benchmark indices ended marginally lower, amid volatile trading session,......